Article Text
Summary
Fingolimod, a sphingosine-1-phosphate receptor modulator, is used for the treatment of relapsing-remitting multiple sclerosis. It is well known to cause bradyarrhythmias. We present a 63-year-old woman who was admitted to the hospital with sustained monomorphic ventricular tachycardia 2 weeks after fingolimod initiation. Further evaluation showed that the patient’s ventricular tachycardia was most likely secondary to her medication. Medical practitioners need to be aware of such possible life-threatening side effects while using fingolimod.
- neurology
- arrhythmias
- drugs and medicines
Statistics from Altmetric.com
Footnotes
Contributors FE and AA took care of the patient in the hospital. Both drafted the manuscript. MLA took care of the patient in the hospital. SAH edited the manuscript, reviewed related literature and agreed the final manuscript.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.